Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
ATTO Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Attovia Therapeutics, Inc.NASDAQ: ATTO
Operating Income · Q2 FY2026 · quarter ended Jun 2026
Operating income of -$21.8M in Q2 FY2026
Q2 FY2026 operating income was -$21.8M.
Context
- Operating income amounted to 4974.7% of revenue in FY2025.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (67.16M) USD
- Year-over-year change
- -61.6%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (67.16M) | -61.6% |
| FY2024 | 2024-12-31 | (41.55M) | — |
Operating Income vs competitors
How ATTO compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -61.6% is the 9th highest of 10, against a peer median of -23.4%.
- Operating income amounts to 4974.7% of revenue for ATTO, versus a peer median of 930.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $40.8M USD | +140.7% | — | 17.6% | |
| LTM Mar 2026 | $21.41M USD | +133.7% | — | 39.8% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | -€48.02M EUR | -54.0% | — | — |
| FY2025 | -$58.07M USD | -158.7% | — | 90740.6% | |
| FY2025 | -$67.16M USD | -61.6% | — | 4974.7% | |
| LTM Mar 2026 | -$80.48M USD | +43.0% | — | 961.9% | |
ZURAZura Bio Limited | LTM Mar 2026 | -$81.49M USD | -23.4% | — | — |
EVMNEvommune, Inc. | LTM Mar 2026 | -$89.99M USD | — | — | 899.9% |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | -$183.11M USD | -45.4% | — | — |
| LTM Mar 2026 | -$267.37M USD | -56.6% | — | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$459M USD | -4.5% | — | 6204.4% |
| Peer median (excluding ATTO) | — | -23.4% | — | 930.9% | |
Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 1.35M |
| Cost of Revenue | 313K | 804K |
| Gross Profit | (313K) | 546K |
| Gross Margin | — | 40.4% |
| Research & Development | 33.86M | 54.15M |
| Selling, General & Admin | 7.38M | 13.55M |
| Operating Expenses | 41.24M | 67.71M |
| Depreciation & Amortization | 313K | 804K |
| EBITDA | (41.24M) | (66.36M) |
| EBITDA Margin | — | -4915.2% |
| Operating Income | (41.55M) | (67.16M) |
| Operating Margin | — | -4974.7% |
| Interest Income | 3.44M | 6.63M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 1.75M | 6.53M |
| Income Before Tax | (39.8M) | (60.63M) |
| Pre-Tax Margin | — | -4490.9% |
| Income Tax Expense | 0 | 0 |
| Net Income | (39.8M) | (60.63M) |
| Net Margin | — | -4490.9% |
| EPS (Basic) | (1.05) | (1.42) |
| EPS (Diluted) | (1.05) | (1.42) |
| Weighted Avg Shares | 43.03M | 43.03M |
| Weighted Avg Shares (Diluted) | 43.03M | 43.03M |
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$15.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.